Top Ten most popular articles on Pharmafile.com this week

pharmafile | June 28, 2019 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Allergan, Bristol-Myers Squibb, China, GSK, Novartis, Takeda, brexit 

This week was diverse as always in terms of news coming out of the pharma industry, but the biggest news was undoubtedly the announcement of a $63 billion mega-merger between AbbVie and Allergan.

However, the story most popular with our readers this week is the news that Takeda intends to vacate all 1,000 of its staff from its US HQ by the end of the year.

10. AstraZeneca’s Imfinzi meets endpoint at Phase 3 interim analysis in extensive-stage small cell lung cancer

AstraZeneca has lifted the curtain on new Phase 3 data for Imfinzi (durvalumab) in the first-line treatment of extensive-stage small cell lung cancer (SCLC), illustrating that the therapy met its primary endpoint in a planned interim analysis carried out by an independent data monitoring committee.

9. Glenmark signs deal with Novartis over distribution in Brazil

Indian firm Glenmark Pharmaceuticals has entered into an agreement with Novartis over the distribution of its respiratory products in Brazil.

8. Sanofi to axe 466 R&D positions in Germany and France

Sanofi has announced that plans to reorganise its research and development operations will result in the losses of 466 jobs across Germany and France as part of a “voluntary departure programme”.

7. Novartis provides promising update on Cosentyx in plaque psoriasis

Novartis has revealed brief new data on its IL-17A antibody Cosentyx (secukinumab) in the treatment off plaque psoriasis, showing that the therapy “improves inflammation and rapidly supresses IL-23” in cases of the disease.

6. GSK offers concessions ahead of planned venture with Pfizer

The European Commission has said that GlaxoSmithKline has offered concessions to address concerns relating to the British multinational’s planned joint venture with Pfizer’s consumer health business.

5. The Brexit ‘cliff edge’: How life sciences can survive

Characterised by a persistent lack of clarity and a political climate that has everyone guessing from week to week, Brexit appears as an impossible challenge for industry. Partners Charlotte Tillett and Gustaf Duhs and Senior Associate Paula Harris of law firm Stevens & Bolton review the trying situation and spell out the best tactics for pharma to survive what could be a messy exit, whenever it may happen.

4. AbbVie poised to acquire Allergan for $63 billion

The industry has been rocked with the announcement of another pharmaceutical mega-merger, as it emerged that AbbVie had sealed an agreement with Allergan to acquire the latter for approximately $63 billion, making it one of the biggest mergers of its kind.

3. Bristol-Myers Squibb to sell off Celgene’s Otezla ahead of $74 billion merger

Bristol-Myers Squibb has agreed to sell off Celgene’s psoriasis treatment Otezla, to appease antitrust regulators.

2. China urges firms to make generic versions of 34 drugs

China’s National Health Commission (NHC) has urged generic drugmakers to pick up the production of 34 drugs that are not currently available as generics.

1. Takeda plans to vacate all 1,000 staff from US HQ by the year’s end

Takeda has announced its plans to vacate all staff from its US headquarters in Deerfield, Illinois, by the end of the year – a hard date was given of 31 December – with the aim of selling the 777,000-square-foot campus by 31 March 2020.

Related Content


GSK’s RSV vaccine approved in EU for older adults

GSK has announced that the European Commission (EC) has authorised Arexvy, the company’s respiratory syncytial …

GSK receives FDA file acceptance for Jemperli plus chemotherapy for treating endometrial cancer

GSK has announced that the US Food and Drug Administration (FDA) has accepted the supplemental …

NICE approves first treatment for obstructive HCM for NHS use

The National Institute for Health and Care Excellence (NICE) has announced that it has approved …

Latest content